Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 5/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15839178 | 0.79 | CYP17A1 (0.45) | CYP11B2SLC6A2PDE9ACYP11B1CYP17A1 | |
| SCHEMBL6653678 | 0.77 | SLC6A2 (0.47) | CYP11B2SLC6A2CYP11B1 | |
| SCHEMBL3017074 | 0.74 | CYP11B2 (0.69) | CYP11B2CYP11B1SMONR3C1CYP1A2 | |
| SCHEMBL24153494 | 0.73 | NR3C1 (0.51) | CYP11B2CYP11B1SMONR3C1PGR | |
| SCHEMBL838162 | 0.70 | SMO (0.51) | CYP11B2CYP11B1SMOIRAK4NR3C1 | |
| Trifluoroacetic Acid SCHEMBL6657105 | 0.70 | L3MBTL1 (0.46) | CYP11B2CYP11B1NR3C1PGR | |
| SCHEMBL4222899 | 0.70 | NR3C1 (0.53) | CYP11B2CYP11B1SMONR3C1 | |
| SCHEMBL839102 | 0.69 | NR3C1 (0.54) | CYP11B2SMONR3C1PGR | |
| SCHEMBL6657272 | 0.68 | IRAK4 (0.50) | CYP11B2IRAK4NR3C1CYP17A1CYP1A2 | |
| SCHEMBL11794 | 0.68 | EGFR (0.46) | CYP11B2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934144-B1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | claimed |
| US-9522141-B2 | Indazole compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-12-20 | — | — | US | claimed |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | claimed |
| EP-2934144-B1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9522141-B2 | Indazole compounds as aldosterone synthase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2934144-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014099833-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885SLC6A2 2629/4885PDE9A 2216/4885 |
| US-20150320733-A1 | INDAZOLE COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HSD11B1, CYP21A2, CYP11B1 | CYP11B2 4/4885SLC6A2 973/4885PDE9A 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.